Lv31
350 积分 2022-10-16 加入
Can the Reduction in Percent LDL Cholesterol or Attained LDL Cholesterol Levels or Both Add Incremental Prognostic Value?
2天前
已完结
Early Initiation of PCSK9 Inhibitor Therapy Versus Placebo in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
2天前
已完结
Clinical impact of ≥ 50% reduction of low density lipoprotein cholesterol following lipid lowering therapy on cardiovascular outcomes in patients with acute coronary syndrome
2天前
已完结
Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease
4天前
已完结
Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial
10天前
已完结
Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial
18天前
已完结
Febuxostat leads to better cardiovascular outcomes compared to allopurinol in patients with advanced chronic kidney disease: A Population-based Cohort Study
18天前
已完结
Allopurinol, Febuxostat, and Nonuse of Xanthine Oxidoreductase Inhibitor Treatment in Patients Receiving Hemodialysis: A Longitudinal Analysis
18天前
已完结
Hyperuricemia and its related diseases: mechanisms and advances in therapy
19天前
已完结
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial
22天前
已完结
皖公网安备34019202002308
